Abstract Body

Background

Twice-yearly subcutaneous lenacapavir (LEN) is a HIV-1 capsid (CA) inhibitor approved for HIV pre-exposure prophylaxis (PrEP) based on efficacy and safety from the PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) Phase 3 studies. The primary analyses demonstrated that acquisition of HIV while receiving LEN and emergent resistance during the studies were rare. Here, we describe the updated resistance analyses for PURPOSE 1 and 2 through the end of the randomized blinded phase.

Methods

Genotypic analyses of HIV-1 CA, reverse transcriptase (RT), protease, and integrase were performed for all participants in the resistance analysis population (RAP), which comprised participants who acquired HIV-1 infection through the randomized blinded phase of the studies and had an HIV RNA viral load of >200 copies/mL.

Results

Since the primary efficacy analyses, 2 people assigned to LEN acquired HIV in PURPOSE 1 and 1 additional person in the LEN group acquired HIV in PURPOSE 2. In PURPOSE 1, an additional 21 people acquired HIV in the oral F/TAF (n=13) and F/TDF groups (n=8), and in PURPOSE 2, 3 additional people acquired HIV on F/TDF. Cumulatively, the PURPOSE 1 RAP included 77 participants (2 LEN; 51 F/TAF; 24 F/TDF). The CA resistance-associated N74D substitution was identified in 1 participant in the LEN group, diagnosed at Study Day 365. The other participant in the LEN group received their final dose on Study Day 183 and acquired HIV in the PK tail phase at Study Day 670 while on F/TDF; no resistance to either study drug was observed. The RT resistance mutation M184V/I was identified in 4 participants (3 F/TAF; 1 F/TDF), and the K65R RT mutation in 1 F/TAF participant with M184V/I. Cumulatively, the PURPOSE 2 RAP included 15 participants (3 LEN; 12 F/TDF). Of the 3 participants who received LEN, 2 developed the N74D substitution (in the primary analysis) while the third participant in the LEN group (new to the current analysis) developed Q67H+K70R. In the F/TDF group, the M184V substitution was observed in 1 participant at the primary analysis, with no additional resistance observed in this analysis.

Conclusions

Twice-yearly subcutaneous LEN was highly efficacious for HIV prevention throughout the randomized blinded phase of PURPOSE 1 and 2. Resistance to LEN remained rare and was observed only in the context of functional LEN monotherapy, a pattern consistent with other PrEP agents. These findings reinforce LEN’s potential as a durable and effective long-acting PrEP option.